Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

NCT05284799 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: OVX836 480µg
BIOLOGICAL: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
BIOLOGICAL: Placebo

Sponsor

Osivax

Collaborators

[object Object]
[object Object]
[object Object]